Board of Directors
Peter D. Meldrum was a co-founder and has been a director of the Company since its inception in May 1991. He has served as president and chief executive officer of Myriad since November 1991. Prior to founding the Company, Mr. Meldrum was president and chief executive officer of Founders Fund, Inc., a venture capital group. He received a Doctor of Engineering degree (honorary) from the University of Utah in 2009, a Doctor of Science degree (honorary) from Westminster College in 2004, an M.B.A. degree from the University of Utah in 1974, and a B.S. degree in Chemical Engineering from the University of Utah in 1970.
Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.
Dennis Langer, M.D., J.D. is a Director of the Company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.